In last trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 1,218,477 shares changing hands with its beta currently measuring 2.3. Company’s recent per share price level of $95.39 trading at -$2.29 or -2.34% at ring of the bell on the day assigns it a market valuation of $6.69 Billion. That closing price of CRSP’s stock is at a discount of -10.2% from its 52-week high price of $105.12 and is indicating a premium of 66.14% from its 52-week low price of $32.3. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 851.88 Million shares which gives us an average trading volume of 862.04 Million if we extend that period to 3-months.
For CRISPR Therapeutics AG (CRSP), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 18 analysts covering the stock, 2 rated the stock as a Sell while none recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 12 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.18 in the current quarter.
In the face of being in the red today for losing -2.34%, in the last five days CRSP remained trading in the green while hitting it’s week-highest on Thursday, Oct 08 when the stock touched $100 price level, adding 4.61% to its value on the day. CRISPR Therapeutics AG’s shares saw a change of 56.62% in year-to-date performance and have moved 14.46% in past 5-day. CRISPR Therapeutics AG (NASDAQ:CRSP) showed a performance of 17.1% in past 30-days. Number of shares sold short was 4.68 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $96.2 to the stock, which implies a rise of 0.85% to its current value. Analysts have been projecting $31 as a low price target for the stock while placing it at a high target of $140. It follows that stock’s current price would jump +46.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -67.5% for stock’s current value.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Statistics highlight that CRISPR Therapeutics AG is scoring comparatively lower than the scores of other players of the relevant industry. The company added +108.5% of value to its shares in past 6 months, showing an annual growth rate of -503.42% while that of industry is 13.6. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -149.2% in the current quarter and calculating -327.5% decline in the next quarter. This year revenue growth is estimated to drop -98.4% from the last financial year’s standing.
14 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.06 Million for the same. And 14 analysts are in estimates of company making revenue of $2.65 Million in the next quarter that will end in December 01, 2020.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 134.1% while estimates for its earnings growth in next 5 years are of 0%
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders are in possession of 20.94% of company’s total shares while institution are holding 55.73% percent of that, with stock having share float percentage of 70.5%. Investors also watch the number of corporate investors in a company very closely, which is 350 institutions for CRISPR Therapeutics AG that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at CRSP for having 6.48 Million shares of worth $476.45 Million. And as of June 29, 2020, it was holding 9.24% of the company’s outstanding shares.
The second largest institutional holder is Versant Venture Management, LLC, which was holding about 4.18 Million shares on June 29, 2020. The number of shares represents firm’s hold over 5.96% of outstanding shares, having a total worth of $307.41 Million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 4091443 shares of worth $349.65 Million or 5.83% of the total outstanding shares. The later fund manager was in possession of 2.05 Million shares on July 30, 2020, making its stake of worth around $175.27 Million in the company or a holder of 2.92% of company’s stock.